Dexcom grows 15% YOY, taps new CEO

SAN DIEGO - Dexcom reported revenue growth of 15% year-over-year to $1.157 billion for the second quarter of 2025.  

Of that, U.S. revenue grew 15% and international revenue grew 16% on a reported basis year-over-year. 

“During the quarter, Dexcom delivered strong revenue results, presented compelling clinical data at ADA, and further advocated for expanded coverage in key growth markets,” said Kevin Sayer, chairman and CEO. “In the second half of 2025, we look forward to continuing our commercial momentum while advancing our product portfolio with the highly-anticipated launch of our Dexcom G7 15 Day System.” 

Second quarter 2025 highlights 

• Received FDA clearance for Dexcom G7 15 Day CGM System. 

• Launched AI-based Smart Food Logging feature, simplifying the process of meal logging for our customers. 

• Enhanced the Stelo customer experience with new software features, broader distribution, and digital health partnerships. 

2025 annual guidance 

Dexcom is raising fiscal year 2025 guidance for revenue, and reiterating guidance for non-GAAP gross profit margin, non-GAAP operating margin, and adjusted EBITDA margin at the following levels: 

• Revenue of $4.600 - $4.625 billion (14-15% growth) 

• Non-GAAP gross profit margin of approximately 62% 

• Non-GAAP operating margin of approximately 21% 

New CEO, Jan.1, 2026 

Dexcom also announced the promotion of Jake Leach to CEO and the board of directors, effective Jan. 1, 2026. Current CEO Kevin Sayer will continue to work closely with Leach during the transition period and will remain executive chairman of the board of directors at the point of transition. 

“Today’s announcement of Jake’s transition to the role of chief executive officer reflects the board’s comprehensive succession planning and their confidence in Jake’s leadership throughout his tenure,” said Sayer. “We are confident that he is the right leader to build on Dexcom’s momentum and extend the company’s growth well into the future.” 

Leach has helped steer the company’s biosensing platforms since the launch of its first commercial system. He has held roles of increasing responsibility across his 21-year tenure with the company. He served as executive vice president and chief technology officer from 2018 through 2022, transitioning to executive vice president and COO in late 2022. In May 2025, he was promoted to the expanded role of president and COO, assuming the additional responsibility of oversight for the company’s strategy and corporate development efforts.